Where does Sam Donato rank among its competitors?

Sam Donato ranks 115th amongst 126 active competitors, of which 12 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Biolexis Therapeutics, which secured $1.6M in May, 2026.

Who are the top competitors of Sam Donato?

Sam Donato's top competitors include Taizhou Baiying Biotechnology, Sanyou Biopharmaceuticals and Procognia. Among them, Biolexis Therapeutics secured the most recent funding round in May, 2026.

Sam Donato - 2026 Company Profile & Competitors

Sam Donato is an unfunded company. It operates as a Provider of bioinformatics data analysis and fungal strain development services. Sam Donato has not raised any funding yet. The company has 126 active competitors, including 12 funded and 5 that have exited. Its top competitors include companies like Taizhou Baiying Biotechnology, Sanyou Biopharmaceuticals and Procognia.

Company Details

Provider of bioinformatics data analysis and fungal strain development services. This entity designs data architectures and automated pipelines for biological systems. It supports large-scale fungal strain programs by managing selection, optimization, and resource protocols. Technical activities include laboratory information management system design, multi-omics integration, and machine learning model development. Services also encompass research informatics, including data governance, database development, and automated reporting systems. Additional technical advisory supports biotechnology research strategy, experimental design, and technology stack evaluation.

Key Metrics

Stage

Unfunded

Ranked

115^th among 126 active competitors

Similar Companies

Taizhou Baiying Biotechnology & 141 more

View Sam Donato's full profile

Sam Donato has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sam Donato include Taizhou Baiying Biotechnology, Sanyou Biopharmaceuticals and Procognia. Here is the list of Top 10 competitors of Sam Donato, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Taizhou Baiying Biotechnology 2012, Taizhou (China), Series B	Provider of antibody-drug research and development services	-	Haitong Bank, CoStone Capital & 10 others	50/100
2nd	Sanyou Biopharmaceuticals 2015, Shanghai (China), Series B	CRO focused on providing cell and molecular biology services for antibody drug discovery	-	LH Ventures, Haier & 3 others	45/100
3rd	Procognia 2000, Rehovot (Israel), Public	Contract research services for glycosylation and protein function studies	$23.8M	Apax, SCP Vitalife & 2 others	35/100
4th	FerroptoCure 2022, Chiyoda City (Japan), Series A	Provider of ferroptosis drug discovery and development solutions	$3.12M	Tokyo Institute of Technology, Tokyo University of Science Innovation Capital ... & 8 others	34/100
5th	Hyku Biosciences 2023, Lexington (United States), Seed	Covalent medicines platform for expanding the boundaries of drug discovery	$62.6M	RA Capital Management, Novartis Venture Fund ... & 5 others	34/100
6th	Whizbang Bioresearch 2018, Chennai (India), Unfunded	CRO focused offering cell and molecular biology services for preclinical drug discovery	-	-	31/100
7th	Cytorum 2020, Santa Clara (United States), Funding Raised	Provider of single cell analysis services using cytometry-based platforms	-	HHS	30/100
8th	Capital Biosciences 2006, Gaithersburg (United States), Funding Raised	Provider of cell and molecular biology-based products and services	-	Business Innovation Network, HHS	30/100
9th	Biolexis Therapeutics 2021, Salt Lake City (United States), Series A	CRO focused on drug discovery of small molecule therapeutics	$14.1M	Clarke Capital Partners	29/100
10th	Sunsai Pharma Equipments 2006, Thane (India), Unfunded	Manufacturer of pharmaceutical processing equipment	-	-	29/100
115th	Sam Donato Unfunded	Provider of bioinformatics data analysis and fungal strain development services	-	-	16/100